Estrogen replacement during hypoalbuminemia may enhance atherosclerotic risk

Journal of the American Society of Nephrology

Volumn 8, Issue 12, 1997, Pages 1870-1876

  Joles, Jaap A ^a,d   Bijleveld, Caspaar ^b   Van Tol, Arie ^c   Geelen, Math J H ^b   Koomans, Hein A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; DOXORUBICIN; ESTRADIOL; ESTROGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY RISK; ESTROGEN METABOLISM; ESTROGEN THERAPY; FEMALE; HORMONE RECEPTOR INTERACTION; HYPERLIPIDEMIA; HYPOALBUMINEMIA; NEPHROTIC SYNDROME; NONHUMAN; ONCOTIC PRESSURE; OVARIECTOMY; PRIORITY JOURNAL; RAT;

EID: 0031430095     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. The Writing Group for the Postmenopausal Estrogen/Progestin Interventions Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women [Erratum appears in JAMA 274:1676, 1995], JAMA 273: 199-208, 1995
2. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328: 1069-1075, 1993
3. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265: 1861-1867, 1991
4. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH: Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105-1110, 1987
5. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325: 1196-1204, 1991
6. Glueck CJ, Fallat RW, Scheel D: Effects of estrogenic compounds on triglyceride kinetics. Metabolism 24: 537-545, 1975
7. Grundy SM, Vega GL: Hypertriglyceridemia: Causes and relation to coronary heart disease. Semin Thromb Hemostasis 14: 149-164, 1988
8. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44: 638-642, 1993
9. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS: The hyperlipidemia of the nephrotic syndrome: Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312: 1544-1558, 1985
10. Rabelink AJ, Hené RJ, Erkelens DW, Joies JA, Koomans HA: Effects of simvastatin and cholestyramine on lipoprolein profile in hyperlipidaemia of the nephrotic syndrome. Lancet ii: 1335-1338, 1988.
11. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Vallès M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323: 579-584, 1990
12. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ: Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest 93: 204-211, 1994
13. Dullaart RPF, Gansevoort RT, Dikkeschei BD, de Zeeuw D, de Jong PE, van Tol A: Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 44: 91-97, 1993
14. Jungst D, Caselmann WH, Kutschera P, Weisweiler P: Relationship of hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome. Clin Chim Acta 168: 159-167, 1987
15. Baxter JH, Goodman HC, Havel RJ: Serum lipid and lipoprotein alterations in nephrosis. J Clin Invest 39: 455-465, 1960
16. Davies RW, Staprans I, Hutchison FN, Kaysen GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86: 600-605, 1990
17. Joles JA, Bijleveld C, van Tol A, Geelen MJH, Koomans HA: Plasma triglyceride levels are higher in nephrotic than in analbuminemic rats despite a similar increase in hepatic triglyceride secretion. Kidney Int 47: 566-572, 1995
18. Joles JA, Willekes-Koolschijn N, van Tol A, Geelhoed-Mieras MM, Danse LHJC, van Garderen E, Erkelens DW, Koomans HA: Hyperlipoproteinemia in analbuminemic rats. Atherosclerosis 88: 35-47, 1991
19. Takahashi M, Kusumi K, Shumiya S, Nagase S: Plasma lipid concentrations and enzyme activities in Nagase analbuminemia rats (NAR). Exp Anim 32: 39-46, 1983
20. Joles JA, Bijleveld C, van Tol A, Geelen MJH, Koomans HA: Ovariectomy decreases plasma triglyceride levels in analbuminemic rats by lowering hepatic triglyceride secretion. Atherosclerosis 117: 51-59, 1995
21. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 29: 502-510, 1986
22. Tijburg LBM, Maquedano A, Bijleveld C, Guzmán M, Geelen MJH: Effects of ethanol feeding on hepatic lipid synthesis. Arch Biochem Biophys 267: 568-579, 1988
23. Bijleveld C, Geelen MJH: Measurement of acetyl-CoA carboxylase activity in isolated hepatocytes. Biochim Biophys Acta 918: 274-283, 1987
24. Steiner G, Haynes FJ, Yoshino G, Vranic M: Hyperinsulinemia and in vivo very-low-density lipoprotein-triglyceride kinetics. Am J Physiol 246: E187-E192, 1984
25. van Tol A, Jansen EJHM, Koomans HA, Joles JA: Characterization of hyperlipoproteinemia in Nagase analbuminemic rats: Effects of pravastatin, an HMG-CoA reductase inhibitor, on plasma apolipoproteins, lipoprotein profile and lecithin: Cholesterol acyltransferase activity. J Lipid Res 32: 1719-1728, 1991
26. Dallinga-Thie GM, Groot PHE, van Tol A: Electroimmunoassay of rat apolipoproteins A-I, A-IV and E: A procedure for sample treatment to increase the sensitivity in diluted fractions. J Lipid Res 26: 889-892, 1985
27. Kovanen PT, Brown MS, Goldstein JL: Increased binding of low density lipoprotein of liver membranes from rats treated with 17α-ethinyl estradiol. J Biol Chem 254: 1367-1373, 1979
28. Staels B, Jansen H, van Tol A, Stahnke G, Will H, Verhoeven G, Auwerx J: Development, food intake, and ethinylestradiol influence hepatic triglyceride lipase and LDL-receptor mRNA levels in rats. J Lipid Res 31: 1211-1218, 1990
29. Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 83: 8370-8374, 1986
30. Angelin B, Olivecrona H, Reihnér E, Rudling M, Stahlberg D, Eriksson M, Ewerth S, Henriksson P, Einarsson K: Hepatic cholesterol metabolism in estrogen-treated men. Gastroenterology 103: 1657-1663, 1992
31. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J: Metabolism of apolipoprotein-B containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 40: 129-138, 1991
32. Vaziri ND, Liang KH: Down-regulation of hepatic LDL-receptor expression in experimental nephrosis. Kidney Int 50: 887-893, 1996
33. Walsh BW, Li H, Sacks FM: Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35: 2083-2093, 1994
34. Brinton EA: Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 16: 431-440, 1996
35. Applebaum-Bowden D, McClean P, Steinmetz A, Fontana D, Matthys C, Warnick GR, Cheung M, Albers JJ, Hazzard WR: Lipoprotein, apolipoprotein and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 30: 1895-1906, 1989
36. Colvin PL Jr, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D: A dose-response relationship between sex hormone-induced changes in hepatic triglyceride lipase and high-density lipoprotein cholesterol in post-menopausal women. Metabolism 40: 1052-1056, 1991
37. Staels B, Auwerx J, Chan L, van Tol A, Rosseneu M, Verhoeven G: Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. J Lipid Res 30: 1137-1145, 1989
38. van't Hooft FM, van Gent T, van Tol A: Effect of 17α-ethinylestradiol on the catabolism of high-density lipoprotein apolipoprotein A-I in the rat. Atherosclerosis 67: 23-31, 1987
39. Wilcox HG, Kenagy R, Weinstein I, Heimberg M: Alterations of plasma lipids and apolipoproteins in female rats treated with ethynyl estradiol. Biochim Biophys Acta 666: 348-355, 1981
40. Calandra S, Gherardi E, Fainaru M, Guaitani A, Bartosek I: Secretion of lipoproteins, apolipoprotein A-I and apolipoprotein E by isolated and perfused liver of rat with experimental nephrotic syndrome. Biochim Biophys Acta 665: 331-338, 1981
41. Tarugi P, Calandra S, Chan L: Changes in apolipoprotein A-I mRNA level in the liver of rats with experimental nephrotic syndrome. Biochim Biophys Acta 868: 51-61, 1986
42. Sun X, Jones H Jr, Joles JA, van Tol A, Kaysen GA: Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol 262: F755-F761, 1992
43. Marsh JB: Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25: 1619-1623, 1984
44. Joles JA, van Tol A, Jansen EJHM, Koomans HA, Rabelink TJ, Grond J, van Goor H: Plasma lipoproteins and renal apolipoproteins in rats with chronic Adriamycin nephrosis. Nephrol Dial Transplant 8: 831-838, 1993
45. Staels B, van Tol A, Verhoeven G, Auwerx J: Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. Endocrinology 126: 2153-2163, 1990
46. Dallinga-Thie GM, van't Hooft FM, van Tol A: Tissue sites of degradation of high density lipoprotein apolipoprotein A-IV in rats. Arteriosclerosis 6: 277-284, 1986
47. Kekki M, Nikkilä EA: Plasma triglyceride metabolism in the adult nephrotic syndrome. Eur J Clin Invest 1: 345-351, 1971
48. McKenzie IFC, Nestel PJ: Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome. J Clin Invest 47: 1685-1694, 1968
49. De Chalain TMB, Michell WL, Berger GMB: Hyperlipidemia, pregnancy and pancreatitis. Surg Gynecol Obstet 167: 469-473, 1988
50. Glueck CJ, Christopher C, Mishkel MA, Tsang RC, Mellies MJ: Pancreatitis, familial hypertriglyceridemia, and pregnancy. Am J Obstet Gynecol 136: 755-761, 1980
51. Glueck CJ, Lang J, Hamer T, Tracy T: Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 123: 59-64, 1994
52. Titanji R, Paz-Guevara A: Hypertriglyceridemia: Severe type V hyperlipidemia in a young woman. Md Med J 41: 231-233, 1992
53. Molitch ME, Oill P, Odell WD: Massive hyperlipemia during estrogen therapy. JAMA 227: 522-525, 1974
54. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ: Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 41: 1193-1198, 1992
55. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 91: 1952-1958, 1995
56. de Sain-van der Velden MGM, Kaysen GA, Joles JA, Voorbij HAM, Koomans HA, Rabelink TJ: Fibrinogen levels are increased as a result of increased synthesis and decreased fractional catabolism in nephrotic patients [Abstract]. J Am Soc Nephrol 7: 1331, 1996
57. Joles JA, Willekes-Koolschijn N, Braam B, Kortlandt W, Koomans HA, Dorhout Mees EJ: Colloid osmotic pressure in young analbuminemic rats. Am J Physiol 257: F23-F28, 1989